You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 11,053,214

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,053,214 protect, and when does it expire?

Patent 11,053,214 protects REYVOW and is included in one NDA.

This patent has forty-five patent family members in thirty-seven countries.

Summary for Patent: 11,053,214

Patent landscape, scope, and claims:

Title:	Compositions and methods related to pyridinoylpiperidine 5-HT.sub.1F agonists
Abstract:	The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-y- l]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.
Inventor(s):	Allieri; Brigida (Verona, IT), Fagan; Paul (Cambridge, MA), Sharp; Emma (London, GB), Skwierczynski; Raymond D. (Cambridge, MA)
Assignee:	CoLucid Pharmaceuticals, Inc. (Indianapolis, IN)
Application Number:	16/467,208
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,053,214

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		ACUTE TREATMENT OF MIGRAINE	⤷ Subscribe
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		ACUTE TREATMENT OF MIGRAINE	⤷ Subscribe
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		ACUTE TREATMENT OF MIGRAINE	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,053,214

PCT Information
PCT Filed	December 05, 2017	PCT Application Number:	PCT/US2017/064652
PCT Publication Date:	June 14, 2018	PCT Publication Number:	WO2018/106657

International Family Members for US Patent 11,053,214

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017373784	⤷ Subscribe
Brazil	112019010934	⤷ Subscribe
Canada	3043772	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.